Spravato is a first-of-its-kind medication to help manage treatment-resistant depression, according to the pharmaceutical company. The nasal spray can be given to people who haven’t seen improvements ...

J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.

Using a simple blood draw, the TriVerity system spits out three scores to ER personnel within 30 minutes that determine if ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...